Lloyd J. Old

112.1k total citations · 29 hit papers
722 papers, 85.7k citations indexed

About

Lloyd J. Old is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lloyd J. Old has authored 722 papers receiving a total of 85.7k indexed citations (citations by other indexed papers that have themselves been cited), including 402 papers in Immunology, 372 papers in Molecular Biology and 251 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lloyd J. Old's work include Immunotherapy and Immune Responses (312 papers), Monoclonal and Polyclonal Antibodies Research (231 papers) and Glycosylation and Glycoproteins Research (143 papers). Lloyd J. Old is often cited by papers focused on Immunotherapy and Immune Responses (312 papers), Monoclonal and Polyclonal Antibodies Research (231 papers) and Glycosylation and Glycoproteins Research (143 papers). Lloyd J. Old collaborates with scholars based in United States, Germany and Australia. Lloyd J. Old's co-authors include Robert D. Schreiber, Gavin P. Dunn, Edward A. Boyse, Elisabeth Stockert, Mark J. Smyth, Hiroaki Ikeda, Barbara Williamson, Yao‐Tseng Chen, Achim A. Jungbluth and E A Carswell and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Lloyd J. Old

712 papers receiving 81.4k citations

Hit Papers

Cancer Immunoediting: Int... 1959 2026 1981 2003 2011 2002 1975 2004 2004 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
    2011 4.6k citations Lloyd J. Old et al. profile →
  2. Cancer immunoediting: from immunosurveillance to tumor escape
    2002 3.7k citations Hiroaki Ikeda, Lloyd J. Old et al. profile →
  3. An endotoxin-induced serum factor that causes necrosis of tumors.
    1975 3.5k citations E A Carswell, Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →
  4. The Three Es of Cancer Immunoediting
    2004 2.2k citations Lloyd J. Old et al. profile →
  5. The Immunobiology of Cancer Immunosurveillance and Immunoediting
    2004 2.1k citations Lloyd J. Old et al. profile →
  6. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
    2001 2.1k citations Hiroaki Ikeda, Lloyd J. Old et al. profile →
  7. Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
    2005 1.9k citations Eiichi Sato, Hiroyoshi Nishikawa et al. Proceedings of the National Academy of Sciences profile →
  8. Antibody therapy of cancer
    2012 1.7k citations Andrew M. Scott, Lloyd J. Old et al. profile →
  9. Tumor Necrosis Factor (TNF)
    1985 1.6k citations Lloyd J. Old profile →
  10. Cancer/testis antigens, gametogenesis and cancer
    2005 1.3k citations Andrew J.G. Simpson, Achim A. Jungbluth et al. profile →
  11. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
    1998 1.1k citations Elisabeth Stockert, Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →
  12. Adaptive immunity maintains occult cancer in an equilibrium state
    2007 1.0k citations Lloyd J. Old et al. profile →
  13. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
    1997 1.0k citations Ali O. Güre, Barbara Williamson et al. Proceedings of the National Academy of Sciences profile →
  14. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
    2012 932 citations James P. Allison, Lloyd J. Old et al. profile →
  15. The roles of IFNγ in protection against tumor development and cancer immunoediting
    2002 724 citations Hiroaki Ikeda, Lloyd J. Old et al. profile →
  16. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
    2002 713 citations Ali O. Güre, Achim A. Jungbluth et al. profile →
  17. Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
    2010 695 citations Junko Matsuzaki, Sacha Gnjatic et al. Proceedings of the National Academy of Sciences profile →
  18. Characterization of tumor necrosis factor-deficient mice
    1997 675 citations Barbara Williamson, Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →
  19. A new class of murine leukemia virus associated with development of spontaneous lymphomas.
    1977 634 citations Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →
  20. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.
    1990 604 citations Pilar Garin‐Chesa, Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →
  21. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
    1998 594 citations Elke Jäger, Julia Karbach et al. profile →
  22. A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
    1998 593 citations Elisabeth Stockert, Elke Jäger et al. profile →
  23. The cancer/testis genes: review, standardization, and commentary.
    2004 560 citations Andrew J.G. Simpson, Lloyd J. Old et al. PubMed profile →
  24. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.
    1979 536 citations Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →
  25. ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS*
    1962 408 citations Lloyd J. Old, E A Carswell et al. profile →
  26. Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse
    1959 387 citations Lloyd J. Old, Baruj Benacerraf et al. profile →
  27. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
    1976 376 citations Lloyd J. Old et al. Proceedings of the National Academy of Sciences profile →
  28. Immunology of Experimental Tumors
    1964 359 citations Lloyd J. Old et al. profile →
  29. Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    2011 254 citations Erika Ritter, Gerd Ritter et al. Proceedings of the National Academy of Sciences profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Lloyd J. Old 47.4k 33.7k 33.2k 13.0k 7.5k 722 85.7k
Ira Pastan 20.3k 0.4× 30.0k 0.9× 45.5k 1.4× 11.7k 0.9× 10.2k 1.4× 1.2k 90.1k
Drew M. Pardoll 46.7k 1.0× 45.0k 1.3× 23.5k 0.7× 3.7k 0.3× 6.0k 0.8× 403 83.2k
Robert D. Schreiber 48.3k 1.0× 33.6k 1.0× 20.7k 0.6× 3.6k 0.3× 4.6k 0.6× 385 79.6k
James P. Allison 50.0k 1.1× 39.1k 1.2× 13.1k 0.4× 4.7k 0.4× 5.1k 0.7× 487 72.3k
Steven A. Rosenberg 88.6k 1.9× 90.3k 2.7× 38.0k 1.1× 8.7k 0.7× 21.2k 2.8× 962 141.4k
Tak W. Mak 34.0k 0.7× 22.6k 0.7× 49.6k 1.5× 3.6k 0.3× 5.8k 0.8× 710 96.1k
Timothy A. Springer 43.4k 0.9× 11.4k 0.3× 26.0k 0.8× 16.3k 1.3× 4.8k 0.6× 536 91.5k
Wolf H. Fridman 31.2k 0.7× 27.6k 0.8× 16.6k 0.5× 6.3k 0.5× 2.2k 0.3× 529 57.4k
Mark J. Smyth 52.9k 1.1× 37.6k 1.1× 20.2k 0.6× 2.7k 0.2× 3.7k 0.5× 595 81.6k
Klaus Rajewsky 41.7k 0.9× 11.3k 0.3× 30.1k 0.9× 11.3k 0.9× 6.7k 0.9× 505 77.2k

Countries citing papers authored by Lloyd J. Old

Since Specialization
Citations

This map shows the geographic impact of Lloyd J. Old's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd J. Old with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd J. Old more than expected).

Fields of papers citing papers by Lloyd J. Old

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lloyd J. Old. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd J. Old. The network helps show where Lloyd J. Old may publish in the future.

Co-authorship network of co-authors of Lloyd J. Old

This figure shows the co-authorship network connecting the top 25 collaborators of Lloyd J. Old. A scholar is included among the top collaborators of Lloyd J. Old based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lloyd J. Old. Lloyd J. Old is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matsuzaki, Junko, Takemasa Tsuji, Immanuel F. Luescher, et al.. (2013). Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells. Cancer Immunology Research. 2(4). 341–350. 38 indexed citations
2.
Karbach, Julia, Antje Neumann, Kathrin Brand, et al.. (2012). Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity. Clinical Cancer Research. 18(19). 5449–5459. 79 indexed citations
3.
Jungbluth, Achim A., Maurizio DiLiberto, Xiangao Huang, et al.. (2011). MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin. Clinical Cancer Research. 17(13). 4309–4319. 79 indexed citations
4.
Nishikawa, Hiroyoshi, Daisuke Muraoka, Linan Wang, et al.. (2010). Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. Clinical Cancer Research. 16(10). 2781–2791. 106 indexed citations
5.
Karbach, Julia, Antje Neumann, Akin Atmaca, et al.. (2010). Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients. Clinical Cancer Research. 17(4). 861–870. 63 indexed citations
6.
Gnjatic, Sacha, Nasser K. Altorki, Derek Ng Tang, et al.. (2009). NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells. Clinical Cancer Research. 15(6). 2130–2139. 58 indexed citations
7.
Qian, Feng, Jeannine Villella, Paul K. Wallace, et al.. (2009). Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer. Cancer Research. 69(13). 5498–5504. 118 indexed citations
8.
Nishikawa, Hiroyoshi, Takuma Kato, Yuki Orito, et al.. (2008). Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. Cancer Research. 68(14). 5948–5954. 66 indexed citations
9.
Bioley, Gilles, Philippe Guillaume, Immanuel F. Luescher, et al.. (2008). HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine. Clinical Cancer Research. 15(1). 299–306. 15 indexed citations
10.
Kiyamova, Ramziya, Vitalina Gryshkova, Beatrice W.T. Yin, et al.. (2008). Development of Monoclonal Antibodies Specific for the Human Sodium-dependent Phosphate Co-transporter NaPi2b. Hybridoma. 27(4). 277–284. 18 indexed citations
11.
Sharma, Padmanee, Yu Shen, Sijin Wen, et al.. (2006). Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma. Clinical Cancer Research. 12(18). 5442–5447. 75 indexed citations
12.
Güre, Ali O., Ramon Chua, Barbara Williamson, et al.. (2005). Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer. Clinical Cancer Research. 11(22). 8055–8062. 294 indexed citations
13.
Old, Lloyd J.. (2004). Unlocking the semantics of Roget's Thesaurus.. Edinburgh Napier Research Repository (Edinburgh Napier University). 2 indexed citations
14.
Lee, Fook-Thean, Pilar Garin‐Chesa, John E. Park, et al.. (2003). Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.. PubMed. 2(8). 729–37. 28 indexed citations
15.
Nishikawa, Hiroyoshi, Hiroaki Ikeda, Miho Sakakura, et al.. (2001). Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proceedings of the National Academy of Sciences. 98(25). 14571–14576. 62 indexed citations
16.
Tanswell, P., Pilar Garin‐Chesa, Wolfgang J. Rettig, et al.. (2001). Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology. 51(2). 177–180. 1 indexed citations
17.
Tanswell, P., Pilar Garin‐Chesa, Wolfgang J. Rettig, et al.. (2001). Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology. 51(2). 177–180. 37 indexed citations
18.
Rettig, Wolfgang J., Pilar Garin‐Chesa, John H. Healey, et al.. (1993). Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.. PubMed. 53(14). 3327–35. 161 indexed citations
19.
Mattes, M. Jules, J. Gregory Cairncross, Lloyd J. Old, & Kenneth O. Lloyd. (1983). Monoclonal Antibodies to Three Widely Distributed Human Cell Surface Antigens. Hybridoma. 2(3). 253–264. 52 indexed citations
20.
Old, Lloyd J., et al.. (1961). Increased phagocytic activity of the res produced by transmissible agent derived from transplantable tumors. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ira Pastan Breakdown of academic impact, for papers by Drew M. Pardoll Breakdown of academic impact, for papers by Robert D. Schreiber Breakdown of academic impact, for papers by James P. Allison Breakdown of academic impact, for papers by Steven A. Rosenberg Breakdown of academic impact, for papers by Tak W. Mak Breakdown of academic impact, for papers by Timothy A. Springer Breakdown of academic impact, for papers by Wolf H. Fridman Breakdown of academic impact, for papers by Mark J. Smyth Breakdown of academic impact, for papers by Klaus Rajewsky
Rankless by CCL
2026